Department of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.
J Cancer Surviv. 2022 Oct;16(5):1055-1064. doi: 10.1007/s11764-021-01096-6. Epub 2021 Sep 11.
The aim of this study is to assess the societal burden of colorectal cancer (CRC) survivorship 2-10 years post-diagnosis in terms of (1) societal costs, and (2) quality of life/utilities, and to analyze associated patient characteristics.
This is a cross-sectional, bottom-up prevalence-based burden of disease study, conducted from a societal perspective in the Netherlands. In total, 155 CRC survivors were included. Utilities were measured by the EQ-5D-5L, using the Dutch tariffs. A cost questionnaire was developed to obtain cost information. Subgroup analyses were performed, based on patient characteristics and sensitivity analyses.
Of all CRC survivors, 81(54%) reported no problems for mobility, 133(88%) for self-care, 98(65%) for daily activities, 59(39%) for pain/discomfort, and 112(74%) for anxiety/depression on the EQ-5D-5L. The average EQ-5D-5L utility score was 0.82 (SD = 0.2) on a scale from 0 (death) to 1 (perfect health). Significant differences in utility score were found for gender, tumor stage, number of comorbidities, and lifestyle score. The average societal costs per CRC survivor per 6 months were estimated at €971 (min = €0, max = €32,425). Significant differences in costs were found for the number of comorbidities.
This study shows a considerable burden of CRC survivors 2-10 years after diagnosis, in comparison with survivors sooner after diagnosis and with healthy individuals in the Netherlands.
Long-term care of CRC survivors should focus on improving the societal burden by identifying modifiable factors, as summarized in the WCRF/AICR lifestyle score, including body composition, physical activity, and diet.
本研究旨在评估 2-10 年诊断后结直肠癌(CRC)生存者的社会负担,具体包括(1)社会成本,(2)生活质量/效用,并分析相关患者特征。
这是一项从社会角度出发,在荷兰进行的基于横断面、自下而上的疾病负担研究。共纳入 155 例 CRC 幸存者。使用荷兰关税,通过 EQ-5D-5L 量表测量效用。开发了成本问卷以获取成本信息。根据患者特征和敏感性分析进行了亚组分析。
所有 CRC 幸存者中,81 人(54%)报告在移动、自理、日常活动、疼痛/不适和焦虑/抑郁方面无任何问题,在 EQ-5D-5L 量表上的评分为 59 分(39%)、133 分(88%)、98 分(65%)和 112 分(74%)。EQ-5D-5L 效用评分的平均得分为 0.82(SD=0.2),范围为 0(死亡)至 1(完全健康)。效用评分在性别、肿瘤分期、共病数量和生活方式评分方面存在显著差异。每位 CRC 幸存者每 6 个月的社会平均成本估计为 971 欧元(最小值=0,最大值=32425 欧元)。成本方面存在显著差异与共病数量有关。
与更早诊断后的幸存者和荷兰健康个体相比,诊断后 2-10 年的 CRC 幸存者的负担相当大。
CRC 幸存者的长期护理应重点通过确定可改变的因素来改善社会负担,如 WCRF/AICR 生活方式评分中所总结的,包括身体成分、身体活动和饮食。